What are ALXN stock prices for the last 5 days?
Looking back at ALXN historical stock prices for the last five trading days, on July 15, 2021, ALXN opened at $184.48, traded as high as $184.72 and as low as $180.21, and closed at $180.51. Trading volume was a total of 8.41M shares. On July 16, 2021, ALXN opened at $180.10, traded as high as $181.52 and as low as $179.27, and closed at $180.03.
What is Alexion Pharmaceuticals'stock price?
Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN." What is Alexion Pharmaceuticals' stock price today? One share of ALXN stock can currently be purchased for approximately $182.50. How much money does Alexion Pharmaceuticals make?
What does ALXN stand for?
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of ULTOMIRIS ® (ravulizumab-cwvz) to include children (one month...
What was the price of ALXN on 14th Apr 2022?
Thursday, 14th Apr 2022 ALXN stock ended at $182.50. During the day the stock fluctuated 0% from a day low at $182.50 to a day high of $182.50 . ...
See more
What is Alexion Pharmaceuticals trading at?
Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN." What is Alexion Pharmaceuticals' stock price today? One share of ALXN stock can currently be purchased for approximately $182.50.
When did AstraZeneca acquire Alexion?
The $39bn deal, announced in December 2020, is AstraZeneca's largest ever acquisition: allowing it to move further into immunology with an enhanced scientific presence, and giving it Alexion's lead medicine soliris (eculizumab), among four other approved medicines and a pipeline of 11 molecules.
Who bought Alexion Pharmaceuticals?
AstraZenecaAstraZeneca today completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company's entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.
How much is Alexion worth?
With costs that can reach as much as $2 million per year, the drugs manufactured by Alexion are some of the most expensive drugs worldwide....Alexion Pharmaceuticals.TypeSubsidiaryRevenueUS$6.069 billion (2020)Net incomeUS$603 million (2020)Total assetsUS$18.103 billion (2020)Total equityUS$11.651 billion (2020)12 more rows
What happened to Alxn?
(ALXN) approved the merger with AstraZeneca PLC. The merger closed prior to the market open today July 21, 2021. In anticipation of the closing, the stock was halted immediately following the after-hours session at 8 p.m. on July 20, 2021.
Is Pfizer buying AstraZeneca?
Under the terms of the agreement, Pfizer will make an upfront payment of $550 million to AstraZeneca upon the close of the transaction and a deferred payment of $175 million in January 2019.
Why did AstraZeneca buy Alexion?
The deal is driven by AstraZeneca's desire to build a stronger presence in immunology—and to give its top line an immediate boost. The deal values Alexion at $175 per share, a 45% premium to the Boston biotech's closing price on Friday.
Does AZ own Alexion?
AZ on Wednesday announced the completion of its Alexion acquisition, a week after securing a pivotal nod from the U.K.'s Competition and Markets Authority (CMA).
How much did AstraZeneca buy Alexion for?
AstraZeneca Plc agreed to buy Alexion Pharmaceuticals Inc. for $39 billion in cash and shares, adding a specialist in the treatment of rare diseases and immunology to its portfolio of medications for cancer and other illnesses. The offer values Alexion at $175 a share, a 45% premium to the closing price on Friday.
How many products does Alexion have?
To date, we have five innovative medicines approved for the treatment of seven rare diseases and devastating conditions. Learn more about each of our medicines and the conditions they treat by selecting a product below.
Is Alexion a good company to work for?
Alexion is a great place to work and really focused on the patients needs. The Mission and Culture inspires all levels and areas of the company engaging employees on its continuous growth.
Is Alexion Pharmaceuticals publicly traded?
(NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special meeting... Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the first quarter of 2021.
How did AstraZeneca acquire Alexion?
The acquisition will be undertaken through a US statutory merger in which Alexion shareholders will receive $60 in cash and 2.1243 new AstraZeneca ADSs listed on the Nasdaq exchange for each of their Alexion shares.
Was Alexion bought by AstraZeneca?
AstraZeneca's mega $39 billion takeover of Alexion Pharmaceuticals has come to a close, delivering the British pharma a lucrative portfolio of immunology medicines and a towering presence in rare diseases.
When did Alexion buys Portola?
On July 2, 2020, Alexion completed its acquisition of Portola through the merger of Buyer with and into Portola without a vote of Portola's shareholders pursuant to Section 251(h) of the Delaware General Corporation Law. As a result of the merger, Portola became a wholly owned subsidiary of Alexion.
When did Astra and Zeneca merger?
1999In 1999, Zeneca and Astra merged to form a new company called AstraZeneca. The merger deal was valued at $67 billion. It was billed as one of the largest ever European mergers at the time of the deal.
Is Alexion Pharmaceuticals stock a Buy, Sell or Hold?
Alexion Pharmaceuticals stock has received a consensus rating of hold. The average rating score is and is based on 7 buy ratings, 8 hold ratings, a...
What was the 52-week low for Alexion Pharmaceuticals stock?
The low in the last 52 weeks of Alexion Pharmaceuticals stock was 175.55. According to the current price, Alexion Pharmaceuticals is 103.96% away f...
What was the 52-week high for Alexion Pharmaceuticals stock?
The high in the last 52 weeks of Alexion Pharmaceuticals stock was 187.45. According to the current price, Alexion Pharmaceuticals is 97.36% away f...
What are analysts forecasts for Alexion Pharmaceuticals stock?
The 15 analysts offering price forecasts for Alexion Pharmaceuticals have a median target of 158.80, with a high estimate of 200.00 and a low estim...
How were Alexion Pharmaceuticals' earnings last quarter?
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) posted its quarterly earnings results on Thursday, April, 29th. The biopharmaceutical company reported...
How often does Alexion Pharmaceuticals pay dividends? What is the dividend yield for Alexion Pharmaceuticals?
Alexion Pharmaceuticals declared a quarterly dividend on Wednesday, October 27th. Investors of record on Monday, November 8th will be given a divid...
Who are Alexion Pharmaceuticals' key executives?
Alexion Pharmaceuticals' management team includes the following people: Dr. Ludwig N. Hantson , CEO & Director (Age 58, Pay $4.25M) Dr. Aradhana...
What is Ludwig Hantson's approval rating as Alexion Pharmaceuticals' CEO?
43 employees have rated Alexion Pharmaceuticals CEO Ludwig Hantson on Glassdoor.com . Ludwig Hantson has an approval rating of 75% among Alexion P...
Who are some of Alexion Pharmaceuticals' key competitors?
Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Rege...
What other stocks do shareholders of Alexion Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Scien...
What is Alexion Pharmaceuticals' stock symbol?
Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."
Who are Alexion Pharmaceuticals' major shareholders?
Alexion Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Ancora Advisors L...
Which major investors are buying Alexion Pharmaceuticals stock?
ALXN stock was purchased by a variety of institutional investors in the last quarter, including Ancora Advisors LLC. View insider buying and selli...
About Alexion Pharmaceuticals
Headlines
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.
Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions
Was The Smart Money Right About Piling Into Microchip Technology Incorporated (MCHP)?
Barchart Technical Opinion
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Alexion Pharmaceuticals stock.
Business Summary
The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.